MIG-2: Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

Sponsor
University of Washington (Other)
Overall Status
Completed
CT.gov ID
NCT00194649
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH)
8
1
1
7
1.1

Study Details

Study Description

Brief Summary

The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men.

We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive.

Condition or Disease Intervention/Treatment Phase
  • Drug: Miglustat (Zavesca)
Phase 4

Detailed Description

Glycosphingolipids (GSL) are a main constituent of the sperm cell membrane in mammals. Male mice deficient in enzymes involved in GSL synthesis have severely impaired fertility and knockout mice are infertile. Recently, it was demonstrated that administration to mice of an inhibitor of ceramide-specific glycosyltransferase, the first step in the biosynthetic pathway of GSL formation, resulted in reversible infertility without discernable adverse side effects. This inhibitor was Miglustat, which is an alkylated imino sugar. The impact of Miglustat therapy on human spermatogenesis is unknown. If the effects on sperm morphology and motility are similar to those observed in mice, Miglustat or other GSL inhibitors might have potential utility as non-hormonal male contraceptives.

Study Design

Study Type:
Interventional
Actual Enrollment :
8 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study
Study Start Date :
Jun 1, 2005
Actual Primary Completion Date :
Jan 1, 2006
Actual Study Completion Date :
Jan 1, 2006

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

100 mg Miglustat BID (twice daily) for six weeks

Drug: Miglustat (Zavesca)
100 mg Miglustat BID (twice daily) for six weeks
Other Names:
  • Zavseca
  • Outcome Measures

    Primary Outcome Measures

    1. The impact of GSL inhibition on human spermatogenesis, if impairment is seen with Miglustat administration, larger contraceptive efficacy studies of Miglustat or other inhibitors of GSL's will be performed. [3 months]

    Secondary Outcome Measures

    1. Safety [3 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 50 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Healthy male, normal lab test
    Exclusion Criteria:
    • Abnormal lab test, history or evidence of significant chronic or acute medical illness, previous or current ethanol or anabolic steroid abuse.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Washington Seattle Washington United States 98195

    Sponsors and Collaborators

    • University of Washington
    • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    Investigators

    • Principal Investigator: John Amory, University of Washington

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00194649
    Other Study ID Numbers:
    • 04-3806-D
    • U54HD042454
    First Posted:
    Sep 19, 2005
    Last Update Posted:
    Sep 19, 2008
    Last Verified:
    Sep 1, 2008
    Keywords provided by , ,
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 19, 2008